KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $16.4 million.

  • Sarepta Therapeutics' Share-based Compensation fell 66.54% to $16.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.8 million, marking a year-over-year decrease of 18.31%. This contributed to the annual value of $205.1 million for FY2024, which is 12.39% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Share-based Compensation of $16.4 million as of Q3 2025, which was down 60.60% from $41.6 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Share-based Compensation registered a high of $102.9 million during Q2 2022, and its lowest value of $16.4 million during Q3 2025.
  • Its 3-year average for Share-based Compensation is $44.8 million, with a median of $46.6 million in 2025.
  • In the last 5 years, Sarepta Therapeutics' Share-based Compensation surged by 254.80% in 2022 and then plummeted by 66.54% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Share-based Compensation stood at $29.7 million in 2021, then skyrocketed by 69.82% to $50.5 million in 2022, then decreased by 9.30% to $45.8 million in 2023, then grew by 20.66% to $55.3 million in 2024, then slumped by 66.54% to $16.4 million in 2025.
  • Its last three reported values are $16.4 million in Q3 2025, $41.6 million for Q2 2025, and $46.6 million during Q1 2025.